Total income (in thousands CZK), income per 1 employee according to FTE, and summary of applied results in the period 2011 – 2017
Parameter | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
FTE* | 187(292) | 195(304) | 204(326) | 247 (311) | 272 (329) | 376 (333) | 284 (335) |
Income from national R&D funding | 168 955 | 161 334 | 277 368 | 253 909 | 338 544 | 304 128 | 310 632 |
Income from international grants | 14 916 | 936 | 5 093 | 3 059 | 8 961 | 6 649 | 23 823 |
Institutional funding | 145 636 | 149 837 | 126 401 | 123 895 | 155 997 | 194 431 | 196 823 |
Contractual research and sale of R&D services | 27 052 | 22 714 | 9 414 | 14 250 | 14 929 | 11 874 | 15 152 |
Total income | 356 559 | 334 821 | 418 276 | 395 113 | 518 431 | 517 082 | 546 430 |
Total per 1 researcher** | 1907(1221) | 1717(1101) | 2050(1283) | 1600(1270) | 1906(1576) | 1375(1553) | 1924(1631) |
* In the parentheses, the numbers of the institute researchers are given.
For the purposes of this statistics, a researcher is an employee of category V1-V6, i.e., research assistant, PhD student, postdoctoral fellow, research fellow, scientist, and senior scientist.
** In the parentheses, the income per numbers of the Institute employees is given.
List of Utility Models
Seifert D, Jelínek P, Marešová L, Sedláček J, Lebeda O, Ráliš J, Holčák P: Screening container for solid-state target. |
Seifert D, Jelínek P, Marešová L, Sedláček J, Lebeda O, Holčák P: Automated microfluid system. |
Seifert D, Jelínek P, Marešová L, Sedláček J, Lebeda O: Mikrofluidní chemický čip pro značení monoklonálních protilátek radionuklidy. |
Hozák P, Šlouf M, Nebesářová J, Moša M, Krivjanská M: Assembly of mutually recognizable nanoparticles for multiple ultrastructural labeling. |
List of Patents
Brynda J, Cígler P, Grüner B, Řezáčová Maloy P, Mader P, Šícha V, Bakardjiev M, Holub J, Dzubak P, Hajduch M: Inhibidores de anhidrasa carbónica y método de su producción. |
Bartůněk P, Kořínek V, Pombinho A, Tůmová L: Monensin-containing pharmaceutical composition for the treatment of familiar adenomatous polyposis. |
Havlík M, Kaplánek R, Dolenský B, Rak J, Bříza T, Džubák P, Hajdúch M, Konečný P, Štěpánková J, Králová J, Král V: Asymmetric Troger bases with hydrazone group and their use in the treatment of oncologic diseases. |
Kaplánek R, Bříza T, Havlík M, Rak J, Kejík Z, Džubák P, Hajdúch M, Konečný P, Štěpánková J, Králová J, Král V: Dioxocyclobutenyl hydrazones and their anticancer activity. |
Kaplánek R, Jakubek M, Havlík M, Rak J, Bříza T, Džubák P, Hajdúch M, Konečný P, Štěpánková J, Králová J, Král V: Caffeine-8-hydrazones as novel cytostatics for the treatment of oncologic diseases . |
Rak J, Kaplánek R, Štulcová T, Drašar P, Havlík M, Bříza T, Džubák P, Hajdúch M, Konečný P, Štěpánková J, Králová J, Král V: Cholyl hydrazones and their use in the treatment of tumor and leukemia diseases. |
Kaplánek R, Bříza T, Havlík M, Rak J, Kejík Z, Džubák P, Hajdúch M, Konečný P, Štěpánková J, Králová J, Král V: Benzothiazole- substituted cyclobut-3-ene-1, 2-dione-3-hydrazones and their use in the treatment of various types of leukemia and tumor diseases. |
Kaplánek R, Havlík M, Rak J, Králová J, Král V: Troger base derivatives and cytostatic properties thereof. |
Grekov I, Pombinho A, Šíma M, Kobets T, Bartůněk P, Lipoldová M: Pharmaceutical composition containing diphenyleneiodonium for treating diseases caused by parasites of Trypanosomatidae species. |
Král V, Králová J, Martásek P, Bříza T, Kejík Z: Use of polymethine salts as sensors for tumor markers. |
Flieger M, Stodůlková E, Kolařík M, Man P, Černý J, Císařová I, Králová J: Submersible strains Quambalaria sp. CCM 8372 and CCM 8373, mixture of naphthoquinone dyes produced thereby, method of their production and use . |
Hozák P, Šlouf M, Nebesářová J, Moša M, Krivjanská M: Set of mutually recognizable nanoparticles, process of their preparation as well as their use for multiple ultra-structural identification. |
Rak J, Kaplánek R, Král V, Králová J, Štulcová T, Drašar P: Conjugates of hydrazones with cholic acid as novel cytostatics. |
Král V, Bříza T, Kejík Z, Králová J, Rimpelová S, Ruml T, Martásek P: Use of polymethine salts as mitochondrial probes. |
Brynda J, Cígler P, Grüner B, Řezáčová Maloy P, Mader P, Šícha V, Bakardjiev M, Holub J, Dzubak P, Hajduch M: Carbonic anhydrase inhibitors and method of their production. |
Brynda J, Cígler P, Grüner B, Řezáčová Maloy P, Mader P, Šícha V, Bakardjiev M: Carbonic anhydrase inhibitors and process for their preparation. |
Kaplánek R, Rak J, Král V, Králová J: Phathalazin-1-ylhydrazones and their use in the treatment of tumor diseases. |
Novák P, Sedlák D, Bartůněk P, Kotora M: Ligands of estrogen receptors α and β, method of their preparation, and pharmaceuticals comprising them. |
Rejman D, Pohl R, Bartůněk P, Ribeiro Pombinho A, Krasny L, Latal T: Lipophosphonoxins, method of their preparation and use. |
Rejman D, Pohl R, Bartůněk P, Riberio Pombinho Antonio José, Krásný P, Látal T: Lipophosphonoxins, their preparation and use. |
Smetana K, Dvořánková B, Lacina L, Strnad H, Kolář M, Chovanec M, Plzák J, Čada Z, Vlček Č, Szabo P, Betka J, Motlík J, Kovářová H, Jarovská K: Combination of antibodies or their Fab fragments for use as drugs and pharmaceutical compositions containing these antibodies or fragments thereof. |
Smetana K, Dvořánková B, Lacina L, Strnad H, Kolář M, Chovanec M, Plzák J, Čada Z, Vlček Č: Combination of monoclonal antibodies or their Fab fragments for use as drugs and pharmaceutical compositions containing these antibodies or fragments thereof. |
Novák P, Sedlák D, Bartůněk P, Kotora M: Ligands of estrogen receptors α and β, method of their preparation, and pharmaceuticals comprising them. |
Hejnar J, Šenigl F: Regulatory promoter/enhancer element protected from DNA methylatian and transcriptional silencing. |
Král V, Bříza T, Kejík Z, Králová J, Poučková P: Use of multimodal systems for preparation of therapeutic and diagnostic tools for management of malignant diseases. |
Selected results of cooperation with commercial sphere and other organizations obtained during implementation of IMG projects in the years 2010 - 2013
License agreement with company Seattle Genetics (for cDNA encoding a specific monoclonal antibody). Application: construction of a potential therapeutic product |
Aptamer inhibiting the enzymatic activity of Taq DNA polymerase. Application: Prototype kit for Hot start PCR with aptamer inhibiting the Taq DNA polymerase enzymatic activity. Supported by Technological Agency of the Czech Republic, partner organization:Top-Bio, s.r.o. |
Experimental development of multimodal holographic microscope – revolutionary prototype of a microscope based on incoherent holography. Partner organizations contributing to the project: TESCAN, a.s., Technical Institute in Brno (VUT) |
Utilization of nanofibre carriers to transport stem cells for medical purposes. Result obtained during implementation of project Biocompatible nanofibre scaffolds forming novel drug matrices for the application of biologically and pharmacologically active substances. Collaborating partners: company Elmarco s.r.o., Institute of Experimental Medicine AS CR, v. v. i., Institute of Macromolecular Chemistry AS CR, v. v. i. |
Recombinant Strep-TRItag-TRAIL expression plasmid for selective precipitation of TRAIL-TRAIL-R complexes. Preparation and characterization of monoclonal antibody against cytoskeletal protein NFH. Preparation and characterization of monoclonal antibodies recognizing human protein Abraxas-1. Plasmids expressing recombinant proteins hAPP-IgG and hAPLP2-IgG. Preparation and characterization of human protein LGR5 and polyclonal antibodies recognizing human protein LGR5. Results obtained in implementing the project “Centre for Molecular and Cellular Immunology”. These results are applied in practice by companies Exbio Praha a.s. and Apronex, s.r.o. Collaborating partners: Institute of Microbiology AS CR, v. v. i., Faculty of Science, Charles University Prague; companies Exbio Praha a.s., Apronex s.r.o. |
Preparation of monoclonal antibodies against proteins CLIC5a, LARGE and OPAL1. Results obtained in implementing the project “Centre for Molecular and Cellular Immunology”. These results are applied in practice by company Apronex s.r.o. Collaborating partners: 2nd Faculty of Medicine, Charles University Prague; company Apronex s.r.o. |
Fifteen hybridoma cell lines prepared as part of the project “Structure and Disorders of the Cell Nucleus Nucleoskeleton – Identification and Diagnostics”. Collaborating partner: company KRD s.r.o. |
Nanoparticles conjugated with antibodies of hybridoma cell lines 2E3-41, 3B6-3, 4C6-37, 5G3-51, 6B4-56, 6B4-57, 6D6-16 a 6D6-34, prepared as part of the project “Novel Nanoparticles for Ultrastructural Diagnostics”. Collaborating partner: company Central European Biosystems s.r.o. |
Construction of nanofibre carriers with incorporated cyclosporin A and carrying stem cells for therapeutic purposes. Result obtained during implementation of project “Biocompatible Nanofibre Scaffolds Forming Novel Drug Matrices for the Application of Biologically and Pharmacologically Active Substances”. Collaborating partners: company Elmarco s.r.o., Institute of Experimental Medicine AS CR, v. v. i., Institute of Macromolecular Chemistry AS CR, v. v. i. |
Novel universal qPCR mixes. Result obtained during implementation of project “Nano-PCR, Ultrasensitive Test for Detection of Specific Proteins in Body Fluids”. Collaborating partners: 3rd Faculty of Medicine, Charles University in Prague, Psychiatric Centre Prague, companies Vidia, s.r.o., Top-Bio s.r.o. |
Novel method for establishment of low protein concentrations in complex biological fluids using nano-iPCR. Result obtained during implementation of project: “Nano-PCR, Ultrasensitive Test for Detection of Specific Proteins in Body Fluids”. Collaborating partners: 3rd Faculty of Medicine, Charles University in Prague, Psychiatric Centre Prague, companies Vidia, s.r.o., Top-Bio s.r.o. |
Certified methodology – Qualitative proof of viral vaccine antigens. Result obtained during implementation of project: “Novel Nanoparticles for Ultrastructural Diagnostics”. Collaborating partner: company SEVAPHARMA a.s. |
Monoclonal antibodies 2E3.H3.F2, 4C6.D12.D2, 5G3.E1.G9, 5G3.E5.A8 a 6B4.E9.B4 conjugated with golden rods. Result obtained during implementation of project: “Novel Nanoparticles for Ultrastructural Diagnostics”. Collaborating partner: company Central European Biosystems s.r.o. |
Monoclonal antibodies 2E3.H3.F2, 3B6.0.C7, 4C6.D12.D2, 5G3.E5.A8, 6B4.E9.B4, 6B4.E9.B6, 6B4.E9.B12 a6D6.F10.D12 conjugated with cubic palladium nanoparticles. Result obtained during implementation of project: “Novel Nanoparticles for Ultrastructural Diagnostics”. Collaborating partner: company Central European Biosystems s.r.o. |
Applied research with participation of IMG researchers (mostly in collaboration with biotech companies) possesses clear economic potential. In the past 15 years, the IMG employees founded seven spin-off biotech companies, which operate independently and develop dynamically. Detailed information on these companies is mentioned below:
Apronex s.r.o. http://www.apronex.cz/ |
Focused on research, development and production of biologically active recombinant proteins. |
Cellvia s.r.o. | Focused on development of small molecule-based drugs; activities are still at the launching phase. |
EXBIO Praha a.s. http://www.exbio.cz/ |
Focused on research, development and production of monoclonal antibodies and recombinant. |
Proteix s.r.o. http://www.proteix.cz/ |
Focused on research, development and production recombinant proteins. |
Top-Bio s.r.o. http://www.top-bio.cz/ |
Focused on development and production of reagents for DNA fragment amplification by polymerase chain reaction. |
In the past 15 years, more than 150 commercially exploited hybridoma cell lines and plasmid constructs for preparation of recombinant proteins have been produced and transferred to implementation partners (Exbio, Apronex, Top-Bio) on contractual basis.
The total commercial turnover based on these products in the past 15 years was more than CZK 200 millions.
Last change: June 19, 2018